Portada›Viernes 12 de diciembre de 2025
Biomédicas del NASDAQ ante la SEC, viernes 12 de diciembre de 2025
Los 43 documentos que 29 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.
← jueves 11 de diciembre de 2025 · lunes 15 de diciembre de 2025 →
El día, bloque a bloque
Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.
Emisiones y dilución
- CTNMContineum Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
- EDSAEdesa Biotech, Inc.424B5Nueva emisión de acciones con precioEDGAR
- GOVXGeoVax Labs, Inc.S-1Capacidad de emisión registradaEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…and may not remain in business. We have received a going concern opinion from our auditors. We have received a "going concern" opinion from our independent registered public accounting firm, reflecting substantial doubt about our ability to continue as a going concern. Our consolidated financial statements contemplate that we will continue as a going concern and do not contain any adjustments that might result if we were unable to continue as a going concern. Our ability…
En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸
…share price, and certain corporate governance requirements. There can be no assurances that we will be able to continue to comply with the applicable listing standards. On July 31, 2025, the “Company received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common…
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
…primarily from sales of our equity securities and from government grants and clinical trial assistance. During 2024, we closed four registered direct offerings of our Common Stock and warrants, as well as established the ATM Program (see footnote 6 to the consolidated financial statements included in this prospectus). Net proceeds to us from these offerings, after deducting commissions to the placement agent and sales agent, as applicable…
- GRIGRI Bio, Inc.424B4Nueva emisión de acciones con precioEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…issue and sell all of the securities registered in this offering, we will require substantial additional capital to advance and complete a Phase 2b clinical trial of GRI-0621. •Our auditors have expressed substantial doubt about our ability to continue as a going concern, and we may not be able to continue as a going concern if we do not obtain additional financing. Risks Related to Research and Development and the Pharmaceutical Industry •Our business is highly dependent…
En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸
…there can be no assurance that the Panel will accept our Compliance Plan or that we will ultimately regain compliance with the Stockholders’ Equity Requirement. In addition, on September 10, 2024, we received a letter from the Staff of Nasdaq indicating that we no longer met the Minimum Bid Price Rule set forth in Nasdaq Listing Rule 5550(a)(2) because the closing bid price for our Common Stock was less than $1.00 for the 30 consecutive business days prior thereto. On February 19, 2025, we filed…
En el documentoContrasplit de accionestexto original ▸
…read this prospectus, together with additional information described under the heading “Where You Can Find More Information” carefully before you invest in any of our securities. On February 21, 2025, we effected a reverse stock split of our Common Stock at a ratio of one-for-17 (the “February 2025 Reverse Stock Split”). Unless otherwise indicated, all financial information, share numbers, option numbers, warrant numbers, other derivative…
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
…derivative security numbers and exercise prices appearing in this prospectus have been adjusted to give effect to the February 2025 Reverse Stock Split. May 2024 At The Market Offering On May 20, 2024, we entered into an At The Market Offering Agreement (the “Sales Agreement”) with Wainwright, pursuant to which we may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0 million of shares of our Common Stock from time…
- IMVTImmunovant, Inc.424B5Nueva emisión de acciones con precioEDGAR
- RNAZTranscode Therapeutics, Inc.S-3Capacidad de emisión registradaEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…registered public accounting firm, and included in such Annual Report and incorporated by reference herein in reliance upon the report (which report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern) upon the authority of said firm as experts in accounting and auditing. WHERE YOU CAN FIND MORE INFORMATION We are subject to the information requirements of the Exchange Act and, in accordance therewith…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 11, 2025, the closing sale price per warrant of our Public Warrants was $0.19. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 11, 2025, the closing sale price per warrant of our Public Warrants was $0.19. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
En el documentoContrasplit de accionestexto original ▸
…Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 11, 2025, the closing sale price per warrant of our Public Warrants was $0.19. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
- SPRBSPRUCE BIOSCIENCES, INC.424B3Prospecto suplementario o de reventaEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…are incorporated by reference in this prospectus. These risks include the following: • We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern. • We will need substantial additional financing to develop our product candidates and implement our operating plan. If we fail to obtain additional financing, we may be forced to delay, reduce or eliminate…
En el documentoContrasplit de accionestexto original ▸
…carefully the section below titled “Special Note Regarding Forward-Looking Statements.” 6 Table of Contents SELECTED FINANCIAL DATA REFLECTING REVERSE STOCK SPLIT Reverse Stock Split On July 23, 2025, we completed a one-for-seventy-five (1:75) reverse stock split of our outstanding common stock, effective as of August 4, 2025, or the Reverse Stock Split. Based on such Reverse Stock Split, the total number of outstanding shares of common stock was adjusted from…
- TLSATiziana Life Sciences Ltd424B5Nueva emisión de acciones con precioEDGAR
- TNYATenaya Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
…our 2021 ESPP that automatically increase the share reserve thereunder each year; and • 50,000,000 shares of common stock issuable upon exercise of Warrants sold in this offering. On August 10, 2022, we entered into a sales agreement with Leerink Partners LLC with respect to an “at-the-market” (ATM) program pursuant to which we may sell up to $75.0 million of shares of our common stock (the ATM Program). As of the date of this prospectus supplement, we have sold an aggregate of 1,358,333 shares of our common…
- ADILADIAL PHARMACEUTICALS, INC.S-3Capacidad de emisión registradaEDGAR
- GNPXGenprex, Inc.424B3Prospecto suplementario o de reventaEDGAR
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
…Additionally, if the holders of Second Private Warrants exercise such warrants in full, we would receive additional net proceeds of approximately $6.1 million. At-The-Market Offering On December 13, 2023, we entered into an At The Market (“ATM”) Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, serving as agent (the “Agent”) with respect to an at-the-market offering program (the “2023 ATM Facility”) under which we may offer and…
- NRXPNRX Pharmaceuticals, Inc.S-3/ACapacidad de emisión registrada (enmienda)EDGAR
- VBIOValion Bio, Inc.424B3Prospecto suplementario o de reventaEDGAR
- VBIOValion Bio, Inc.424B3Prospecto suplementario o de reventaEDGAR
Participaciones y control
- CLLSCellectis S.A.SC 13D/ACambio en participación significativaEDGAR
- IMVTImmunovant, Inc.SC 13D/ACambio en participación significativaEDGAR
- MDGLMADRIGAL PHARMACEUTICALS, INC.SC 13D/ACambio en participación significativaEDGAR
- MDGLMADRIGAL PHARMACEUTICALS, INC.SC 13D/ACambio en participación significativaEDGAR
Informes y hechos relevantes
- BCRXBIOCRYST PHARMACEUTICALS INC8-KOtros hechos relevantesEDGAR
En el documentoLa FDA aprueba el fármacotexto original ▸
…monthly attack rates in APeX-P– RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of an oral pellet formulation of once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years. HAE often presents…
- CDTCDT Equity Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
- ENVBEnveric Biosciences, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
- IDYAIDEAYA Biosciences, Inc.8-KFin de acuerdo materialEDGAR
- JAGXJaguar Health, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
- ALECAlector, Inc.8-KCambio en el consejo o la direcciónEDGAR
En el documentoCambio en la dirección de la empresatexto original ▸
…Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 10, 2025, the board of directors of Alector, Inc. (“Alector”) appointed Neil Berkley as Alector’s Chief Financial Officer. Mr. Berkley had been serving as Interim Chief Financial Officer of Alector since June 2025. Mr. Berkley will continue serving as Chief Business Officer and as the principal financial officer of Alector…
- ARTVArtiva Biotherapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
- CYTKCYTOKINETICS INC8-KOtros hechos relevantesEDGAR
- EDSAEdesa Biotech, Inc.8-KResultadosEDGAR
- EDSAEdesa Biotech, Inc.10-KInforme anualEDGAR
En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸
…and remain profitable would impair our ability to sustain operations and adversely affect the price of our securities and our ability to raise capital. Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern. We have recognized recurring losses, and at September 30, 2025, we had an accumulated deficit of $65.9 million. We anticipate operating losses to continue for the foreseeable future due to, among other…
En el documentoPrograma de venta continua de acciones (ATM)texto original ▸
…provided, however, that a holder may increase or decrease the beneficial ownership limitation by giving 61 days’ notice to the Company, but not to any percentage in excess of 19.99%. In October 2024, we entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC as a sales agent (“HCW ATM”) pursuant to which we may offer and sell, from time to time, common shares through an at-the-market equity offering program for up…
- EDSAEdesa Biotech, Inc.8-KOtros hechos relevantesEDGAR
- EXOZEXOZYMES INC.8-KOtros hechos relevantesEDGAR
- GRIGRI Bio, Inc.8-KNuevo acuerdo materialEDGAR
- GRIGRI Bio, Inc.8-KOtros hechos relevantesEDGAR
- IBRXImmunityBio, Inc.8-KOtros hechos relevantesEDGAR
- IMVTImmunovant, Inc.8-KOtros hechos relevantesEDGAR
- INCYINCYTE CORP8-KCambio en el consejo o la direcciónEDGAR
- LENZLENZ Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
- PRTAPROTHENA CORP PUBLIC LTD CO8-KCambio en el consejo o la direcciónEDGAR
- SCLXScilex Holding Co8-KNuevo acuerdo materialEDGAR
- SPRBSPRUCE BIOSCIENCES, INC.8-KCambio en el consejo o la direcciónEDGAR
- TNYATenaya Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
← jueves 11 de diciembre de 2025 · lunes 15 de diciembre de 2025 →
Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.
Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.